✦ LIBER ✦

Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia

✍ Scribed by Mikkel Krogh-Madsen; Brendan Bender; Morten Krogh Jensen; Ove Juul Nielsen; Lena E. Friberg; Per Hartvig Honoré

Book ID: 113028035
Publisher: Springer
Year: 2012
Tongue: English
Weight: 346 KB
Volume: 69
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-011-1800-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Amsacrine, cytarabine and etoposide in t

Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia

✍ Anders Wahlin 📂 Article 📅 1989 🏛 Springer US 🌐 English ⚖ 463 KB

Induction failures in childhood acute no

Induction failures in childhood acute nonlymphocytic leukemia: Etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine

✍ Kalwinsky, David K. ;Dahl, Gary V. ;Mirro, Joseph ;Jackson, Carl W. ;Look, A. Th 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 595 KB

Mitoxantrone and etoposide with or witho

Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia

✍ Steven M. Trifilio; Alfred W. Rademaker; Diane Newman; Katherine Coyle; Katrin C 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 180 KB

Characterization of vancomycin pharmacok

Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population

✍ Jarkowski, A.; Forrest, A.; Sweeney, R. P.; Tan, W.; Segal, B. H.; Almyroudis, N 📂 Article 📅 2011 🏛 SAGE Publications 🌐 English ⚖ 128 KB

Fludarabine, cytarabine, and G-CSF (FLAG

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia

✍ Montillo, Marco; Mirto, Salvatore; Petti, Maria Concetta; Latagliata, Roberto; M 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB 👁 2 views

Thirty-eight patients with primary resistant or relapsing acute myeloid leukemia (AML) were treated with fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG). Median age was 41 (range 11-70). Sixteen patients had AML that was primary resistant to induction treatment, while 22 wer

Lenalidomide monotherapy and in combinat

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities

✍ Dennis, M.; Culligan, D.; Karamitros, D.; Vyas, P.; Johnson, P.; Russell, N.H.; 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 962 KB